Please assess the completion status of the following clinical trial:

Trial Title: Artegraft Versus Propaten Dialysis Grafts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Candidate for hemodialysis~* Not a candidate for native AV fistula~* In need of a new AV graft in the upper arm location~* Artery and vein \> 3mm.~* Medically stable and have a life expectancy of ≥ 12 months~* The patient or legal guardian understands the study and is willing to comply with the requirements.~Exclusion Criteria:~* \< 18 years of age~* Current history or within 6 months of IV drug abuse~* Chronic hypotension (\<100 mm systolic pressure) not responsive to treatment~* Pregnant or lactating~* Known hypercoagulable state~* Requires only a revision of an existing graft~* Receiving artery or vein is less than 3 mm in diameter at the time of implantation~* Known axillary/subclavian occlusion or stenosis that has not been treated~* Known or suspected systemic infection~* Heparin sensitivity (known HIT)~* Enrolled in another investigational study.~* Subject has more than 1 graft in target limb.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artegraft (Type: ACTIVE_COMPARATOR): Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
- Propaten (Type: ACTIVE_COMPARATOR): Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).